Clinical Capital Conversations

About Clinical Capital Conversations

Welcome to Clinical Capital Conversations! Join host Dr. Peter M. Kovacs, a clinical research pioneer and global investor, as he explores the intersection of science and strategic investment. Discover what it takes to transform medical innovation into scalable impact. Each episode features unfiltered conversations with clinical research leaders, biotech/medtech founders, VCs, and policymakers. Peter shares his firsthand experience, from building agile clinical trial networks to investing in disruptive health tech across Asia and Europe.

Publisher

Dr. Peter M. Kovacs

Category

business

Language

en

Explicit

No

First episode

2 Sept 2025

Latest episode

13 Feb 2026

Latest episodes

18 episodes in the feed.

1. 

   13 Feb 2026

   EP18 - FemTech Is Not a Trend, It Is a Clinical Correction

   FemTech is often framed as a market trend. In this episode of “Clinical Capital Conversations”, Dr. Peter M. Kovacs explains why it is actually a long-overdue clinical correction. Together with Roswitha Verwer, Founder and CEO of “YON E”, and Muskaan Bhan, Chief Clinical Officer, this conversation explores why women were historically excluded from clinical trials, how biased data still shape healthcare AI, and why continuous measurement is changing medicine. This episode is for investors, founders, and healthcare leaders who care about execution, responsibility, and long-term impact, not shortcuts. Timecode: 00:00 Welcome and Introduction 00:50 Progress and Achievements in FemTech 02:16 Strategic Planning and Teamwork 05:18 Challenges in FemTech and AI Development 08:42 Importance of Continuous Data Tracking 12:49 Ethical Considerations and Long-Term Goals 16:20 FemTech Industry Trends and Future Outlook 20:29 Navigating Advisory Roles in a Regulated Era 20:48 The Rise of FemTech and Female Health Initiatives 22:38 Building a Supportive FemTech Community 23:19 Challenges in FemTech Investment 24:34 Investor Conversations and Strategies 30:21 The Importance of Team and Personal Connections 33:08 Future Plans and Closing Remarks Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Guests: Roswitha Verwer LinkedIn: https://www.linkedin.com/in/roswitha-verwer-b2b636137/ (https://www.linkedin.com/in/roswitha-verwer-b2b636137/) Roswitha Verwer Personal Website: https://www.roswithaverwer.com/ (https://www.roswithaverwer.com/) Dr. Muskaan Bhan: https://www.linkedin.com/in/dr-muskaan-bhan-9b7123120/ (https://www.linkedin.com/in/dr-muskaan-bhan-9b7123120/)

2. 

   6 Feb 2026

   EP17 - The Real Risk Is Execution: What Investors Miss When They Fund Science Without Systems

   In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs sits down with Roswitha Verwer (YONE) and Karoly Szanto to unpack what most investors miss in early-stage health innovation: execution is the moat. YONE delivered the majority of a 12-month roadmap in 6 months. We break down how it happened, what systems made it possible, and why femtech fundraising is still biased even when the operating metrics are strong. What we cover: How to build vendor communication into contracts and timelines Running a high-performance global team without losing control Meritocracy, KPIs, and having hard performance conversations with facts Why female founders and femtech still face access barriers to capital The gap stage problem in medtech funding, and why value-driven partners matter Why many accelerators create noise, not outcomes The next milestones for YONE, including the 600,000 co-investment raise and the seed round plan This is a conversation for investors, founders, and operators who want clinical innovation that scales, de-risks, and reaches patients. Timecode: 00:00 Introduction and Welcome 00:21 Achievements and Progress 01:38 Lessons for Startup Founders 02:56 Building a Strong Global Team 04:44 Handling Underperformance 09:36 Future Challenges and Milestones 13:28 Fundraising Challenges for FemTech 27:36 The Importance of Value-Driven Partnerships 31:29 Conclusion and Gratitude Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Guests: Roswitha Verwer: https://www.linkedin.com/in/roswitha-verwer-b2b636137/ (https://www.linkedin.com/in/roswitha-verwer-b2b636137/) Károly Szántó: https://www.linkedin.com/in/karolyszanto1/ (https://www.linkedin.com/in/karolyszanto1/)

3. 

   29 Jan 2026

   EP16 - The Co-Investor Question That Determines Everything in Biotech and Medtech

   This is a continuation of our main conversation on what it takes to turn medical innovation into scalable impact. In this episode, Dr. Peter M. Kovacs sits down with Károly Szántó and Thijmen Meijer to unpack the co-investor question that determines everything in biotech and medtech. If you are building or funding early-stage life sciences, this is the uncomfortable truth: the cap table is a governance system. The wrong co-investors can slow execution, distort milestones, and burn capital. The right co-investors create speed, trust, and real de-risk. What we cover: Why investor labels matter less than incentives and behavior Skin in the game, and why it changes decision quality Two co-investor archetypes that create real synergy How family offices think, and why relationships and values come first Europe versus Asia: differences in investor mindset and culture Why smaller, domain-specific funds are gaining momentum Practical questions founders and investors should ask before partnering Who this is for: Founders in biotech and medtech, healthcare VCs, family offices, corporate venture teams, private equity, and operators building clinical infrastructure. Timecode: 00:00 Introduction to Key Stakeholders 00:22 Types of Co-Investors 01:09 Value Proposition and Commitment 02:10 Investor Specialization and Synergies 03:26 Role of Angel Investors 04:02 Corporate Venture Capital 04:44 Family Offices and Personal Touch 08:56 Challenges in Different Regions 09:32 Building Relationships with Investors 10:34 High Net Worth Individuals 18:02 Micro Funds and Emerging Managers 19:51 Conclusion and Future Outlook Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Guests: Károly Szántó: https://www.linkedin.com/in/karolyszanto1/ (https://www.linkedin.com/in/karolyszanto1/) Thijmen Meijer: https://www.linkedin.com/in/thmnmr/ (https://www.linkedin.com/in/thmnmr/) UniPrisma: https://uniprisma.com/ (https://uniprisma.com/)

4. 

   23 Jan 2026

   EP15 - Europe Has the Science. Asia Has the Capital. The Missing Layer Is Execution.

   Europe has elite science. Asia has a capital. So why do so many European university spinouts never reach venture readiness or exits? In this episode, Dr. Peter M. Kovacs speaks with Károly Szántó and Thijmen Meijer about the real gaps that block deep tech startups, especially in Central and Eastern Europe, and what a modern support model looks like. What we cover: Why most spinouts never become VC fundable The commercialization gap between research and markets Mindset, team design, and why the founder is not always the CEO IP clarity and why it is the first gate to investability Milestones that remove ambiguity and build investor trust Smart money versus dumb money in biotech and medtech How to bridge Europe’s science with Asia’s capital through operators and partnerships Key takeaway: funding is not the goal. Value creation is the goal. Subscribe for more conversations at the crossroads of science and capital. Timecode: 00:00 Introduction and Meeting the Guests 00:16 Challenges Faced by European Startups 04:44 The Importance of Mindset in Commercialization 07:43 Building Effective Teams for Startups 14:04 Investment Challenges and Opportunities 17:15 The Role of Clear Goals and Milestones 21:40 The Investor's Perspective 25:26 Introduction to Portfolio Companies 25:45 The Need for New Investment Models 26:05 Technological Boom and Efficiency 26:29 Building Companies for Impact 27:30 Challenges in Deep Tech Investment 27:50 Value-Driven Founders 29:12 Operational Models and Risk Mitigation 30:50 Identifying Good Partners 32:55 Scaling Up and Future Goals 33:43 Investor and Founder Dynamics 37:09 Cultural Differences in Startups 46:40 Lab Space and Resource Challenges 49:39 Networking and Collaboration 51:57 Preparing for Global Markets Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Guests: Károly Szántó: https://www.karolyszanto.com/ (https://www.karolyszanto.com/) Thijmen Meijer: https://www.thijmenmeijer.com/ (https://www.thijmenmeijer.com/) UniPrisma: https://uniprisma.com/ (https://uniprisma.com/about/)

5. 

   9 Jan 2026

   EP14 - The Operating System Behind Breakthroughs: Why Venture Studios, Focus, and Execution Decide Outcomes in Healthcare

   In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs speaks with Károly Szántó about venture studios, calculated risk, and what it really takes to turn promising innovation into execution. We cover: How a non-linear career becomes a competitive advantage Why focus beats speed in early-stage venture building The difference between high risk and calculated risk What university spinouts are missing, and how to fix it through market partnership How ecosystems change through examples, not speeches What investors should do diligence to avoid science-driven capital burn Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Timecode: 00:00 Introduction and Guest Welcome 00:26 Karoly's Career Journey 01:16 Discovering Sales and Business Development 03:46 Embracing Entrepreneurship 07:55 Building Uni Prisma Venture Studio 08:49 Venture Capital Experience 13:57 Focus on Healthcare and Impact 18:09 Challenges and Future Vision 22:49 Conclusion and Final Thoughts Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Guests: Károly Szántó: https://www.linkedin.com/in/karolyszanto1/ (https://www.linkedin.com/in/karolyszanto1/)

6. 

   18 Dec 2025

   EP13 - Age Management Is Not HR. It Is an Execution Discipline Investors Cannot Ignore

   In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter speak with Michaela Hrdlickova about Age Management and why workforce execution risk is one of the most overlooked variables in healthcare investing. We explore how work ability is measured, why leadership quality drives performance, and how investors can protect long-duration returns by treating human capital as infrastructure. This conversation is essential for biotech founders, healthcare investors, board members, and operators navigating long clinical timelines and execution complexity. Subscribe for more conversations at the crossroads of science and capital. Timecode: 00:00 Introduction to Misa Hrdlickova and Age Management 00:41 The Concept and History of Age Management 03:01 Implementing Age Management in Companies 05:50 Solutions and Processes for Age Management 14:07 Misa Hrdlickova's Background and Career Journey 21:24 Advice for Future Generations 23:09 Conclusion and Final Thoughts Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Guests: Michaela Hrdlickova: https://www.michaelahrdlickova.eu/ (https://www.michaelahrdlickova.eu/) Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/ (https://www.linkedin.com/in/pavlinawalter/)

7. 

   11 Dec 2025

   EP12 - Seeing Through the Noise: The Investor Mindset That Survives Biotech Cycles

   In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter speak with Ales Vavra, a former hedge fund manager known for exposing weaknesses in overhyped biotech companies. Together, they explore what investors often misunderstand about biotech risk, why due diligence fails, how AI is reshaping investment analysis, and the mindset required to survive the volatility of the sector. If you invest in biotech, medtech, or clinical infrastructure, this conversation will challenge your assumptions and sharpen your thinking. Topics covered: • The psychology that misleads biotech investors • Why execution risk matters more than scientific novelty • How AI can support diligence without replacing expertise • The danger of hype cycles in Alzheimer’s, longevity, and obesity • Why diversification and discipline outperform intuition • What separates resilient investors from speculative gamblers Subscribe to Clinical Capital Conversations for more insights at the intersection of science and capital. Timecode: 00:00 Introduction and Guest Background 01:44 Investment Strategies in Healthcare 03:13 Red Flags in Healthcare Investments 06:04 Role of AI in Investment Decisions 08:16 Advice for Healthcare Investors 12:01 Success Stories and Challenges 14:07 The Role of Sugar in Our Lives 14:55 Alcohol Consumption and Life Balance 15:43 The Hype and Reality of AI 18:40 Investment Challenges for Startups 21:48 Bitcoin and Long-Term Value 25:15 Personal Reflections and Future Outlook 26:17 Final Thoughts on Investment and Life Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Guests: Ales Vavra https://www.linkedin.com/in/ales-vavra-6423475/ (https://www.linkedin.com/in/ales-vavra-6423475/) Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/ (https://www.linkedin.com/in/pavlinawalter/)

8. 

   4 Dec 2025

   EP11 - AI Memory Therapy With Real Clinical Impact.

   AI memory therapy is no longer a concept. It is here, clinically validated, and already helping dementia patients feel less lonely and more connected. In this episode of Clinical Capital Conversations, Peter M. Kovacs speaks with Kompanion Care founder Peter Markus about Lilia, an AI-powered therapeutic platform that combines reminiscence therapy, family-generated memories, and digital biomarkers to deliver real clinical impact. We explore: How personal loss shaped the company Why AI can scale proven psychotherapies How clinical validation creates trust Why reimbursement is the true growth path How digital biomarkers will transform early detection If you want to understand where dementia care, digital therapeutics, and AI-driven monitoring are heading, this conversation is essential. Timecode: 00:00 Introduction and Guest Introduction 00:23 Peter Markus's Background and Career Journey 01:26 The Birth of Kompanion Care 04:31 Innovative Technology Behind Lilia Platform 11:41 Challenges and Importance of Medical Software 15:23 Current Progress and Future Plans 22:17 Investment and Market Strategy 37:28 Conclusion and Final Thoughts Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Guests: Péter Márkus: https://www.linkedin.com/in/pmarkus/ (https://www.linkedin.com/in/pmarkus/) Kompanion Care: https://www.kompanioncare.com/ (https://www.kompanioncare.com/)

9. 

   27 Nov 2025

   EP10 - Inside Europe’s AI Hospitals: How Olomouc Built a Clinical Innovation Engine

   Inside Europe, a new type of hospital is emerging. In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter sit down with Antonín Hlavinka, the innovation and digitalization lead at University Hospital Olomouc. Together, explore how one of the largest hospitals in the Czech Republic built a functioning AI ecosystem that is delivering measurable clinical impact today. Discuss certified and experimental clinical AI tools, governance structures, telemedicine innovation, multimodal prediction engines, and real patient cases where AI detected what humans could not. This conversation highlights what investors, clinicians, and health system operators need to understand as Europe moves toward agent-driven hospital environments. If you want a front-row look at the future of digital healthcare, this episode is essential. Timecode: 00:00 Welcome and Introduction 00:24 Role and Responsibilities in Healthcare 01:31 Adoption of AI in Healthcare 02:27 Impact of COVID-19 on Technology Adoption 04:18 AI Applications in Hospitals 04:49 Certified vs. Experimental AI Models 07:47 AI Tools in Use 14:05 Innovation and Project Management 21:41 Introduction to AI in Radiology 22:10 The Evolution of AI in Healthcare 22:55 Challenges and Rapid Developments 23:30 Microsoft's Game-Changing AI Model 24:42 AI in Medical Practice 27:41 AI in Education 28:55 Balancing AI and Human Cognition 30:55 AI's Impact on Healthcare Workforce 33:30 Global Perspectives on AI Adoption 36:42 Future of AI in Hospitals 39:03 Collaborating with Startups and Innovators 40:33 Conclusion and Future Prospects Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Guests: Antonín Hlavinka: https://www.linkedin.com/in/anton%C3%ADn-hlavinka-b045754b/ (https://www.linkedin.com/in/anton%C3%ADn-hlavinka-b045754b/) Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/ (https://www.linkedin.com/in/pavlinawalter/)

10. 

    20 Nov 2025

    InTouch with Humanity: How AI Is Redefining Care and Connection

    Can artificial intelligence bring us closer instead of pulling us apart? In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter speak with Vassili Le Moigne, founder of InTouch, about how AI voice technology is transforming elder care across 89 countries. Together, they explore how scalable empathy, data ethics, and thoughtful design can redefine how we care for aging populations without losing the human touch. Topics covered: The origin of InTouch and its mission to reduce loneliness Voice AI and cognitive engagement for seniors GDPR, data ethics, and protecting user trust The economics of aging and independent living The business of empathy in global health innovation Timecode: 00:00 Starting the Call: A Busy Morning 03:00 Introducing Vassili: Background and Journey 04:51 The Birth of InTouch: Inspiration and Development 08:07 How InTouch Works: Features and Benefits 10:46 Global Reach and Compliance 16:47 Real-Life Impact: Testimonials and Feedback 19:36 Different Approaches for Alzheimer's Patients 21:06 Future Plans and Global Expansion 22:45 Addressing Loneliness Beyond Seniors 23:47 Technical Challenges and Solutions 24:55 Ethical Choices in Voice Selection 25:28 Market Differences: Europe vs. USA 27:58 Cultural Insights and Language Adaptations 30:36 Mentoring and Advice for Startups 34:17 Concluding Thoughts on InTouch Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Guests: Vassili Le Moigne: https://www.linkedin.com/in/vassililemoigne/ (https://www.linkedin.com/in/vassililemoigne/) Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/ (https://www.linkedin.com/in/pavlinawalter/)

11. 

    13 Nov 2025

    The Future of Biologics: How Strategic CROs are Powering the Next Generation of Clinical Research

    Biologics are transforming medicine, but who’s enabling that transformation behind the scenes? In this episode, I sit down with Jiri Raska, Chief Commercial Officer at Quinta Analytica, and Pavlina Walter, to discuss: Why biologics and biosimilars are now the fastest-growing segment in pharma How CROs are evolving from vendors to strategic partners What small biotechs need most to reach clinical milestones Europe’s regulatory turnaround under the new CTIS system The rise of ADCs and how integrated analytics create real competitive advantage Timecode: 00:00 Introduction to Jiri and Quinta Analytica 01:09 Jiri's Background and Passion for Chemistry 01:56 Transition to Business Development 03:43 Current Trends in Biologics and Biosimilars 05:57 Challenges and Opportunities in Clinical Studies 09:17 Supporting Small Biotech Startups 13:08 Customer Success Management 14:47 Expansion and Collaboration 16:43 Future of Personalized Medicine 19:26 Regulatory Challenges in Europe 23:58 Ostrava Subsidiary and Cross-Border Recruitment 27:00 Future Directions for Quinta Analytica 29:50 Jiri's Personal Career Aspirations 31:49 Conclusion and Final Thoughts Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Guests: Jiri Raska: https://www.linkedin.com/in/jiri-raska-pharma/ (https://www.linkedin.com/in/jiri-raska-pharma/) Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/ (https://www.linkedin.com/in/pavlinawalter/)

12. 

    6 Nov 2025

    Leading with Value: Lessons in Leadership, Legacy, and Resilience

    In this episode of Clinical Capital Conversations, I sat down with Pavlina Walter and our guest Jiri Pavlíček, a mentor, entrepreneur, and one of Central Europe’s most respected MedTech leaders. Together, we explored everything from the European MedTech landscape to AI-driven diagnostics, MDR regulation, and the importance of risk-taking culture. From navigating post-Communist transitions to leading a multi-market MedTech enterprise and embracing AI-driven technologies, Jiri’s story reveals what it takes to combine operational excellence with human-centered values. Key themes: Leadership and values in healthcare innovation European MedTech market outlook and MDR challenges AI as the next wave in diagnostics Building teams and trust that scale Resilience, mindset, and long-term impact Timecode: 00:00 Welcome and Introduction 00:28 Jiri's Background and Early Life 01:26 Professional Journey and Achievements 03:49 Founding Aspironix and Business Insights 06:05 Current MedTech Landscape and Challenges 11:58 AI in Medical Devices 14:19 Personal Reflections and Future Goals 17:04 Advice for Startups and Entrepreneurs 19:29 Closing Remarks Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Guests: Jiri Pavlicek: https://www.linkedin.com/in/jiri-pavlicek-7b32b12/ (https://www.linkedin.com/in/jiri-pavlicek-7b32b12/) Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/ (https://www.linkedin.com/in/pavlinawalter/)

13. 

    23 Oct 2025

    Building the Central European Venture Engine: From Founders to Scalable Companies

    In this episode, Peter M. Kovacs speaks with Károly Szántó and Thijmen Meijer, co-founders of Uniprisma, about how Central Europe’s startup scene is maturing from ideas to execution. They discuss founder psychology, team readiness, ego management, and why venture studios are redefining early-stage investment across Europe. Chapters 00:00  Introduction and context 01:10  What Uniprisma is and how it started 05:30  Why founder personality defines success 09:15  When to replace the founder as CEO 14:20  Building high-performance startup teams 18:40  The biggest mistakes in early-stage ventures 23:00  Teaching founders to engage markets early 28:15  Investor perspective on people vs products 33:30  The YON E Health case and early success stories 38:50  How venture studios de-risk early investment 44:00  Central Europe’s innovation potential 49:30  Final reflections If you invest in early-stage ventures or build founder support ecosystems, watch this conversation to understand how execution discipline is becoming Central Europe’s competitive edge. Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome. Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Guests: Károly Szántó: https://www.linkedin.com/in/karolyszanto1/ (https://www.linkedin.com/in/karolyszanto1/) Thijmen Meijer: https://www.linkedin.com/in/thmnmr/ (https://www.linkedin.com/in/thmnmr/)

14. 

    16 Oct 2025

    From Pain to Purpose: Scaling Femtech with Precision and Purpose

    In this episode, Peter M. Kovacs speaks with Roswitha Verwer and Dr. Muskaan Bhan, the founders of YON E Health, about transforming personal trauma into global innovation. They discuss the journey from idea to clinical-grade Femtech, data ethics, diversity in research, and why women’s health is the next major frontier for investors and operators alike. Chapters 00:00  Introduction and context 01:15  How Roswitha and Muskaan met 04:30  The personal story behind YON E Health 08:10  What pH and temperature tell us about women’s health 12:25  Building a medical device from concept to clinical validation 18:40  Why diversity in clinical data matters 23:00  Regulatory roadmap and CE/FDA pathway 27:30  Investment challenges for female founders 33:00  Data privacy, consent, and trust 39:45  Culture, education, and global adoption 45:20  Team building and advisory governance 52:10  The future of Femtech and Peter’s reflections If you are investing in healthcare or building within Femtech, watch this discussion to understand why precision, transparency, and inclusion are the new performance metrics. Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital.

15. 

    10 Oct 2025

    AI in Europe: Building Bridges Between Policy, Business, and Healthcare

    What will decide the future of AI in Europe: ethics, bureaucracy, or competitiveness? In this episode, I sit down with Jan Kavalírek, Deputy Minister of Industry and Trade and Government Envoy for AI in the Czech Republic, together with Pavlina Walter, to discuss: Why Czechia was the first EU country to propose AI simplification. How regulation can protect safety without paralysing innovation. What Europe must do to close the gap with the US and China. The role of startups and SMEs in building a competitive AI ecosystem. Why AI policy directly impacts healthcare, clinical research, and patient outcomes. Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Timecode: 00:00 Introduction to Jan Kavalirek and His Role 00:52 Goals and Ambitions for AI in Czechia and EU 01:38 Simplifying AI Legislation in the EU 03:16 Challenges and Support for AI Providers 07:05 Collaboration and Competitiveness in AI 12:25 Personal Reflections and Experiences 18:10 Future Prospects and Conclusion Links: Jan Kavalírek : linkedin.com/in/jan-kavalirek-339a1a298 (https://www.linkedin.com/in/jan-kavalirek-339a1a298) Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/ (https://www.linkedin.com/in/pavlinawalter/) Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/)

16. 

    10 Sept 2025

    Who We Are: PMK Group and Our Mission in Biotech

    Who We Are: PMK Group and Our Mission in Biotech | Clinical Capital Conversations Biotech often fails for the wrong reasons. Nearly 60% of clinical trial failures are due to technical execution, not the science itself. In this episode, Dr. Peter M. Kovacs explains why he founded PMK Group, a firm that combines capital with clinical and regulatory expertise to reduce technical failures and accelerate drug development. Why it matters: – Billions are lost to preventable execution failures – Patients wait years for therapies that could be delivered faster – Investors face unnecessary downside risk PMK Group’s model is different: we do not just invest money. We invest experience, systems, and execution. Subscribe to Clinical Capital Conversations for more insights at the crossroads of science and capital. Timecode: 00:00 Introduction to Success in Biotech 00:16 Understanding the Main Risks in Biotech 00:44 Meet the Leader: Peter M. Kovacs 01:06 The PMK Group Difference 01:42 Minimizing Technical Failures 02:09 Supporting Biotech and MedTech Companies 02:32 Vision for the Future 02:58 Call to Collaborate Links: Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) Peter M. Kovacs Personal Website:https://www.petermkovacs.com/ (https://www.petermkovacs.com/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/)

17. 

    2 Sept 2025

    AI and Healthcare Innovation with Lukas Benzel, Pavlina Walter and Peter M. Kovacs

    What does real AI adoption in healthcare look like when you leave the hype behind? In this Prague Episode, I speak with Lukas Benzel, Managing Director of the Czech Association of Artificial Intelligence, and Pavlina Walter. We cover hospital adoption, the shift from sick care to prevention, the role of AI in clinical trials, Europe’s strategic approach, and why Singapore’s model is significant. Practical playbooks for investors, founders, and operators. Chapters 00:00 Welcome and context in Prague 00:35 Who is the Czech AI Association and why it matters 02:10 Hype vs value in AI adoption 04:05 Workshops, education, and finding business value 05:10 Sectors with traction: healthcare, education, defense, public sector 06:20 Health tech in Czech hospitals and regulation reality 07:55 Europe, US, and Asia: where to compete 09:10 Singapore lessons and the AI hub model 12:05 Constraints in hospitals: money, people, data readiness 13:00 Beyond radiology: prevention, trials, and operations 15:10 Patient acceptance, trust, and education 18:05 National AI strategy and public sector adoption 20:05 From basic research to new materials and drugs 21:30 AI for SMEs: pick use cases with ROI 23:00 Is AI a bubble. Why the answer is no 24:15 Productivity, new work, and personal tools 28:40 Cybersecurity and responsible use 31:00 Why an AI association, how to join Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

18. 

    2 Sept 2025

    EP01 From Budapest to Singapore - A Life-Changing Decision

    In this episode, Dr. Peter M. Kovacs shares the story of how a study trip in 2018 transformed his life. Within weeks, he decided to relocate his family to Singapore, a country that would become both his home and the strategic hub for his global healthcare and investment ventures. Why Singapore? A clean, safe, efficient environment A business, biotech, and financial hub Access to Asia’s fast-growing healthcare markets Supportive policies and an innovation-friendly culture This is more than a relocation story. It’s about resilience, vision, and what it means to position yourself at the heart of the world’s most dynamic region. Timecode: 00:00 Why and How I Moved to Singapore 00:04 Starting My Healthcare MBA Journey 00:56 Discovering Singapore 01:27 Making the Move Permanent 01:45 Professional and Personal Benefits of Singapore 02:07 Expanding into the Asian Market 03:20 Singapore: The Ideal Business Hub Links: LinkedIn: https://www.linkedin.com/in/petermkovacs/ (https://www.linkedin.com/in/petermkovacs/) PMK Group Website: https://www.pmk-group.com/ (https://www.pmk-group.com/) Peter M. Kovacs Personal Website: https://www.petermkovacs.com/ (https://www.petermkovacs.com/)

Contact Clinical Capital Conversations

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.